Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Harm Jan Lourens"'
Autor:
Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer, Valerie R. Wiersma
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Acute myeloid leukemia (AML) is a malignancy still associated with poor survival rates, among others, due to frequent occurrence of therapy-resistant relapse after standard-of-care treatment with cytarabine (AraC). AraC triggers apoptotic ce
Externí odkaz:
https://doaj.org/article/744707850025474188f77817ec125057
Autor:
Nienke Visser, Levi Collin Nelemans, Yuan He, Harm Jan Lourens, Macarena González Corrales, Gerwin Huls, Valerie R. Wiersma, Jan Jacob Schuringa, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In recent years, the therapeutic (re)activation of innate anticancer immunity has gained prominence, with therapeutic blocking of the interaction of Signal Regulatory Protein (SIRP)-α with its ligand CD47 yielding complete responses in refractory an
Externí odkaz:
https://doaj.org/article/433d8659aff946d7b49c0e7573e80c22
Autor:
Jimena Álvarez Freile, Yuzhu Qi, Lisa Jacob, Maria Franceskin Lobo, Harm Jan Lourens, Gerwin Huls, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Investigations into the strength of antigen-specific responses in vitro is becoming increasingly relevant for decision making in early-phase research of novel immunotherapeutic approaches, including adoptive cell but also immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/6a90fd200f114efda1abe01601dbe684
Autor:
Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
A higher density of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment, particularly cytotoxic CD8+ T cells, is associated with improved clinical outcome in various cancers. However, local inhibitory factors can suppress T cell activ
Externí odkaz:
https://doaj.org/article/1dd027660af844b49d8b8cf3bd413551
Autor:
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cell
Externí odkaz:
https://doaj.org/article/5b0c52b51ccf44eb9aa17073f9d75dfd
Autor:
Yuan He, Renee Bouwstra, Valerie R. Wiersma, Mathilde de Jong, Harm Jan Lourens, Rudolf Fehrmann, Marco de Bruyn, Emanuele Ammatuna, Gerwin Huls, Tom van Meerten, Edwin Bremer
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-8 (2019)
CD47 is a promising new target in cancer immunotherapy and recently the pro-phagocytic signal SLAMF7 has been shown to have a crucial role in phagocytosis induced by CD47-blocking antibody in hematological tumors. In this study, the authors demonstra
Externí odkaz:
https://doaj.org/article/69bb46c6cb07419c8c3da1b05f0247bc
Autor:
Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer
Publikováno v:
Biomedicines, Vol 10, Iss 5, p 1175 (2022)
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison t
Externí odkaz:
https://doaj.org/article/1da5f0a70400457ca37c839a7d7747c6
Autor:
Natasha Ustyanovska Avtenyuk, Ghizlane Choukrani, Emanuele Ammatuna, Toshiro Niki, Ewa Cendrowicz, Harm Jan Lourens, Gerwin Huls, Valerie R. Wiersma, Edwin Bremer
Publikováno v:
Biomedicines, Vol 10, Iss 1, p 66 (2021)
In earlier studies, galectin-9 (Gal-9) was identified as a multifaceted player in both adaptive and innate immunity. Further, Gal-9 had direct cytotoxic and tumor-selective activity towards cancer cell lines of various origins. In the current study,
Externí odkaz:
https://doaj.org/article/2a67e24bf62345e19fde2b58b24c359c
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 5, p 2337 (2021)
Elevated activation of the autophagy pathway is currently thought to be one of the survival mechanisms allowing therapy-resistant cancer cells to escape elimination, including for cytarabine (AraC)-resistant acute myeloid leukemia (AML) patients. Con
Externí odkaz:
https://doaj.org/article/5921a5ebb62f4e66960a2d8c0cde240f
Autor:
Mariska Sie, Wilfred F A den Dunnen, Harm Jan Lourens, Tiny G J Meeuwsen-de Boer, Frank J G Scherpen, Walderik W Zomerman, Kim R Kampen, Eelco W Hoving, Eveline S J M de Bont
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0122555 (2015)
Up to now, several clinical studies have been started investigating the relevance of receptor tyrosine kinase (RTK) inhibitors upon progression free survival in various pediatric brain tumors. However, single targeted kinase inhibition failed, possib
Externí odkaz:
https://doaj.org/article/d0a6574e0a6e41cba2f071bee0b37e36